The UK’s Department of Health and Social Care is to use Oxford based clinical AI company Sensyne Health‘s technology to read Covid-19 lateral flow diagnostic tests as part of the UK government’s asymptomatic testing programme.
Sensyne as signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use its MagnifEye AI technology.
The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices and selected private sector organisations with large workforces. Revenues will be shared with Excalibur Health Systems under the terms of the exclusive agreement between the two companies.
Excalibur Healthcare Services Limited, founded by Professor Sir Christopher Evans, is a medical supplies company that played a significant part in finding vitally needed ventilators and PPE for the Government early in the Covid-19 pandemic.
Lord (Paul) Drayson CEO of Sensyne Health, said: “This is a significant commercial milestone in Sensyne’s development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic.”